New Risk • Jun 15
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$3.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.2m free cash flow). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$120.7m market cap, or US$86.3m). Announcement • Jun 04
Helix BioPharma Corp. announced that it has received CAD 3.673 million in funding Helix BioPharma Corp. has announced and issued a non-brokered private placement of 3,673 unsecured convertible debentures of the
Company for the principal amount of CAD 3,673,000 pursuant on June 3, 2026. The principal amount and any unpaid accrued interest of the Convertible Debentures will be due and payable 14 months from the closing date of the private placement. Each Convertible Debenture will bear interest at 25% per annum, calculated on a simple interest basis. If the Convertible Debentures are not repaid on or prior to the maturity date, the outstanding principal amount of the Convertible Debentures may be convertible by the holder on the maturity date into common shares in the capital of the Company at a conversion price of CAD 1.42 per share, being the market price of the Shares as of the price reservation date, less the permitted 20% discount in accordance with TSX policies. The Convertible Debentures and any Shares issuable thereunder are subject to a statutory four month hold period commencing on the closing date of the offering. No finder’s fees were paid in connection with the offering. New Risk • May 11
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: CA$125.3m (US$91.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.7m free cash flow). Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$125.3m market cap, or US$91.5m). New Risk • Mar 17
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: CA$136.7m (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.2m free cash flow). Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$136.7m market cap, or US$99.7m). Announcement • Nov 24
Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026 Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026. New Risk • Oct 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 16% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$1.4m). Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (16% average weekly change). Announcement • Aug 23
Helix BioPharma Corp. announced that it has received CAD 1.66675 million in funding Helix BioPharma Corp. announced that it has closed non-brokered private placement to issue 2,222,333 common shares at a price of CAD 0.75 for gross proceeds of CAD 1,666,749.75 on August 22, 2025. The Offering is subject to final approval of the Toronto Stock Exchange, and the Common Shares are subject to a hold period of four months and one day expiring on December 23, 2025, in accordance with applicable securities laws. In connection with the closing of the Offering, the Company will pay finders’ fees to certain eligible finders. New Risk • Jun 13
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$19k). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$69.0m market cap, or US$50.7m). Announcement • May 21
Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million. Helix BioPharma Corp. (TSX:HBP) signed a letter of intent to acquire Oncology assets of Laevoroc Immunology AG on November 12, 2024. Helix BioPharma Corp. (TSX:HBP) entered into a Asset Purchase Agreement to acquire Oncology assets of Laevoroc Immunology AG for CHF 3.7 million on November 28, 2024. As consideration Helix will issue 16.5% of its issued and outstanding shares to Laevoroc. As on November 28, 2024, Helix would be required to issue 8.088553 million common shares based on the Helix's 49,021,536 shares currently issued and outstanding. The companies aim to close definitive agreements before year-end, upon completion of the requisite due diligence. The Transaction is subject to the approval of the Toronto Stock Exchange and certain closing conditions of transactions of a similar nature. The deal is subject to approval of the shareholders of Helix BioPharma Corp. (TSX:HBP).Helix BioPharma anticipates that Transaction will close on or around January 30, 2025 and all shares issuable in connection with the transaction will be subject to a hold period of four months and one day from the date of issuance. As on February 21, 2025, Helix BioPharma announces that its Annual General and Special Meeting for the year ended July 31, 2024, that was to be held by January 31, 2025, has been extended to March 26, 2025 to provide additional time to seek shareholder approval with respect to its proposed asset acquisition from Laevoroc Oncology AG.As on March 26, 2025 , Helix BioPharma shareholders approved the transaction.
Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million on May 20, 2025. In consideration for the transaction, the Company issued 11,555,076 Consideration Shares to Laevoroc Oncology AG. Announcement • May 15
Helix BioPharma Corp. announced that it expects to receive CAD 13 million in funding Helix BioPharma Corp. announced that it will receive CAD 13 million in funding on May 14, 2025. New Risk • Mar 16
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.7m free cash flow). Negative equity (-CA$19k). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (CA$47.7m market cap, or US$33.2m). Announcement • Mar 13
Helix BioPharma Corp. Announces Executive Appointments Helix BioPharma Corp. announced the addition of three esteemed experts in oncology and drug development to its executive team. The appointments underscore Helix's commitment to assembling a world-class team to push the limits of proven science and bring life-changing therapies to patients as soon as possible. Thomas Mehrling, MD, PhD Chief Medical Officer (CMO): Dr. Thomas Mehrling (PhD in Pharmacology and MD, University of Frankfurt) brings 20 years of experience shaping the oncology landscape, with previous roles at Takeda, Mundipharma International and Roche. His track record includes the successful introduction of groundbreaking cancer drugs across Europe, with commercial successes nearing USD 1 billion in sales. As Chief Medical Officer, Dr. Mehrling will lead Helix's clinical development strategy, beginning with Tumor Defence BreakerTM L-DOS47--a first-in-class, clinical-stage antibody- enzyme conjugate (AEC) to enhance the effectiveness of today's immune-oncology therapies for the treatment of Non-Small Cell Lung Cancer (NSCLC). Jonathan Davis, PhD Director of ADC Discovery: A leading expert in therapeutic antibodies, Dr. Davis joins Helix as Director of Antibody-Drug Conjugate (ADC) Discovery. With over 15 years of experience spearheading discovery and innovation strategies across diverse therapeutic antibody formats--including monoclonal antibodies (mAbs), multispecifics, and bi-specific ADCs (EMD Serono, Bristol-Myers Squibb, Invenra)--Dr. Davis will play a pivotal role in advancing Helix's ADC portfolio targeting Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CECAM6). As of 2025, Helix is drawing on the latest advancements in design, conjugation, and payload technology to develop bi-specific ADCs and radionuclide drug conjugates (RDCs) for gastrointestinal, gynecological, and other solid tumors. Dr. Davis's expertise will be instrumental in translating these innovations into next-generation, targeted therapies that enhance efficacy while minimizing toxicity. Dr. Davis received his PhD from University of California, San Francisco, and completed his post-doctoral research at Harvard Medical School. Davide Guggi, PhD Chief Technology Officer (CTO): Bringing extensive Chemistry, Manufacturing, and Controls (CMC) expertise, Dr. Guggi joins Helix as Chief Technology Officer. With over a decade of experience guiding the end-to-end development of small molecules and biologics--including mAbs, ADCs, and radio-immuno conjugates--Dr. Guggi has collaborated with more than 20 global biotech firms to drive regulatory success from discovery through to new drug applications (NDA) and biologics license applications (BLA) across the US, EU, and Canada. Prior to his CMC consultancy, he led oncology business units and commercial departments at Mundipharma International and Gilead, and he received his PhD in Pharmaceutical Technology and Biotechnology from the University of Vienna. Dr. Guggi's leadership will be instrumental in ensuring the seamless clinical development of Helix's compounds while optimizing their scalability for later commercialization, positioning the Company for long-term success in bringing innovative cancer therapies to market. New Risk • Feb 23
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$1.4m). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (CA$52.0m market cap, or US$36.5m). Announcement • Jan 10
Helix BioPharma Corp. announced that it has received CAD 3 million in funding Helix BioPharma Corp. announces that it has closed the private placement of four million common shares of the company at a price of CAD 0.75 per common share for gross proceeds of CAD 3 million. on January 9, 2025. The offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on May 9, 2025, in accordance with applicable securities laws. In connection with the closing, the company paid a cash fee of 105 of gross proceeds raised to an eligible finder. Announcement • Dec 18
Helix BioPharma Corp., Annual General Meeting, Feb 26, 2025 Helix BioPharma Corp., Annual General Meeting, Feb 26, 2025. New Risk • Jun 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$259k). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (CA$53.9m market cap, or US$39.2m). New Risk • May 15
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$259k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$259k). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (CA$48.2m market cap, or US$35.4m). Announcement • Apr 09
Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding On April 8, 2024, Helix BioPharma Corp. closed the transaction. The Offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on August 9, 2024 in accordance with applicable securities laws. In connection with the closing. The company paid a cash fee of 10% of gross proceeds equal to CAD 191,500.005 raised to an eligible finder. Announcement • Mar 30
Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in funding Helix BioPharma Corp announced private placement financing of 12,766,667 common shares of the company at a price of CAD 0.15 per common share for gross proceeds of CAD 1,915,000 on March 28, 2024. The Offering is subject to customary closing conditions including the receipt of all necessary corporate and regulatory approvals, including the approval of the Toronto Stock Exchange. In connection with the closing, the Company will pay a cash fee of 10% of gross proceeds raised to an eligible finder. The Common Shares will be subject to a hold period of four months and one day from the closing date in accordance with applicable securities laws. Announcement • Nov 08
Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024 Helix BioPharma Corp., Annual General Meeting, Jan 18, 2024. New Risk • Oct 29
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$844k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-CA$844k). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (CA$43.3m market cap, or US$31.2m). Announcement • Oct 13
Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Helix BioPharma Corp. announced that the Company will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in the Hynes Convention Center, Boston, via in person attendance, October 11-15, 2023. During the conference, Helix will highlight the enhanced effects of anti-PD1 immunotherapy when combined with L-DOS47 in an orthotopic Pancreatic tumor model in mice. The drug has already been administered to over 120 patients in the clinic across 4 clinical trials and has been shown to be safe and well tolerated. Additionally, L-DOS47 has also demonstrated promising anti-tumor activity across a range of doses, both as monotherapy and in combination with chemotherapy agents. The Company is open to collaborating with the right partner(s) to explore potential synergies with anti-PD1 and other treatment regimens. Poster Presentation Details: Title: Neutralizing Acidosis with ADC L-DOS47 Urease Immunoconjugate Enhances Response to Anti-PD1 Checkpoint Blockade in A Preclinical Orthotopic Model of Pancreatic Adenocarcinoma. Abstract Number: 35494. Poster Presentation Date and Time: October 13, 12:30 pm - 4:00 pm. Location: Level 2, Exhibit Hall D. Poster Session B, Poster Number: B125. Announcement • Aug 24
Helix BioPharma Corp. announced that it expects to receive CAD 2.998 million in funding Helix BioPharma Corp. announced a private placement financing of 16,655,557 common shares at a price of CAD 0.18 per common share for proceeds of CAD 2,998,000 on August 22, 2023. The common shares issued pursuant are subject to a statutory hold period of four months. Helix BioPharma Corp. announces that it has closed the first tranche of private placement financing for
gross proceeds of CAD 2,998,000. Announcement • Aug 23
Helix BioPharma Corp. Announces Executive Changes Helix BioPharma Corp. announced appointment of Mr. Janusz Grabski to the board of directors of the Company with an immediate effect. Mr. Grabski is a lawyer specialized in corporate law and real estate law with over twenty years of experience. Mr. Grabski is based in Warsaw, Poland. Alongside the appointment, the Company also announced resignation of Mr. Christopher Maciejewski from the board of directors of the Company due to personal reasons. Board Change • Jan 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. Member of Scientific & Strategic Advisory Board Robert Gillies is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Nov 18
Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023 Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023. Board Change • Nov 16
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. Member of Scientific & Strategic Advisory Board Robert Gillies is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Nov 04
Helix BioPharma Corp. announced that it has received CAD 4.62902 million in funding Helix BioPharma Corp. announced a private placement financing of 25,716,777 common shares at a price of CAD 0.18 per common share for proceeds of CAD 4,629,019.86 on November 3, 2022. The transaction included participation from directors and insiders of the company. The common shares issued pursuant are subject to a statutory hold period of four months and one day ending on March 4, 2023, in accordance with applicable securities law. In connection with the closing, the company will pay a cash fee of 10% of gross proceeds raised to an eligible finder. Announcement • Oct 05
Helix BioPharma Corp. Appoints Frank Gary Renshaw as Chief Medical Officer Helix BioPharma Corp. announced the appointment of Dr. Frank Gary Renshaw, as the Chief Medical Officer. Dr. Renshaw has been with Helix since December 2019 as a consultant and member of the Scientific and Strategic Advisory Board. He brings more than 20 years experience as a drug developer within the health care industry and has previously provided leadership with his medical and/or scientific expertise, from pre-clinical laboratory and animal tumor model development, to presiding over six successful new drug applications, eight approvals at the EMA, including two biological applications, and more than two dozen successful FIH INDs and EMA new drug submissions. Recently, he has provided further expertise as the Chief Medical Officer, and lead Oncology consultant for several Bio-Pharmaceutical global entities, as well as the Global lead on many radiotherapies, Chemotherapy, Devices, and Immuno-Oncology clinical programs. Dr. Renshaw will bring to Helix BioPharma his several decades of development experience in oncology-hematology, Molecular/Immuno-Oncology drug research. Dr. Frank Gary Renshaw is an Oncologist-Hematologist having completed his training at the medical school at University of Medicine and Dentistry of New Jersey at the Cardeza Foundation and Temple University Skin and Cancer Hospital and was a resident within the Oncology immunology research group at the Cancer Institute of NJ. Subsequent to this, he trained during his Oncology fellowship with the Cancer Immuno-Biological therapy group at MD Anderson Cancer Center and completed a molecular Biology fellowship at the NIH Naval Medical center where he worked on FIH trials of T-Cell therapy. During his academic career he worked as an Oncology consultant and Primary investigator to the Glaxo Smith Kline, Immunex, Chiron, Bristol Myers Squibb, and Sinclair Swine melanoma research, companies. From his academic rolls, Dr. Renshaw was then recruited to chair the US Gastrointestinal Oncology group at Eli Lilly company, leading several early development programs as well as the later stages of drug clinical/research development of Gemcitabine, and including pharmacogenetic/dynamics work for the eventual multiple approvals Pemetrexed for NSCLC and Mesothelioma. Announcement • Sep 02
Helix BioPharma Corp. Appoints Gabrielle M Siegers as Head of Research Development Based Out of its Lab in Edmonton Helix BioPharma Corp. announced the appointment of Dr. Gabrielle M Siegers, MA, Ph.D., as the Head of R&D based out of the Company's lab in Edmonton. Dr. Siegers comes to Helix from IN8bio, where she served as Senior Scientist/Gamma Delta T Cell Specialist. Prior to this, Dr. Siegers was a Research Associate with the Department of Experimental Oncology at the University of Alberta following postdoctoral studies in Dr. Lynne-Marie Postovits laboratory, where she studied how the tumour microenvironment impacts immune cell function. Prior to this, Dr. Siegers was a Postdoctoral Fellow in the laboratory of Dr. Paula Foster, where she continued research begun in the Translational Cell Therapy Program with Dr. Armand Keating at the Princess Margaret Hospital. Gabrielle M. Siegers (HBSc Guelph, MA Queens) obtained her PhD in Molecular Immunology at the Max Planck Institute for Immunobiology and the University of Freiburg, Germany. Ms. Siegers returned to Canada to conduct postdoctoral research at the Princess Margaret Hospital, Robarts Research Institute and Western University, and then worked as a Research Associate at the University of Alberta. In 2021, she became an independent scientific consultant and then signed on full time with IN8bio, dividing time between her home office in Edmonton and the lab in Birmingham, Alabama, USA. In August 2022, Ms. Siegers began a new role in Edmonton as Head of R&D for Helix BioPharma. She has published several original research articles, reviews and book chapters with international and cross-disciplinary collaborators (currently 32 publications on PubMed), and she has given invited talks at national and international meetings in Canada, the United States and Germany. Board Change • Jun 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. No highly experienced directors. Member of Scientific & Strategic Advisory Board Robert Gillies is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • May 20
Helix BioPharma Corp. Appoints Namrata Malhotra as Corporate Secretary Mr. Kawar will be joined by Ms. Namrata Malhotra, who will be assuming the role of Corporate Secretary for Helix BioPharma Corp. Ms. Malhotra serves as a Corporate Secretary with Grove and has an extensive background in corporate governance management and regulatory compliance. Ms. Malhotra has most recently held the position of Assistant Vice-President, Corporate Secretarial and Compliance at a fintech start-up in India. A recent immigrantto Canada, Ms. Malhotra is an experienced Corporate Secretary to public companies in Canada. Announcement • May 19
Helix BioPharma Corp. Appoints Hatem Kawar as Chief Financial Officer Helix BioPharma Corp. announced the appointment of Mr. Hatem Kawar as the Company's Chief Financial Officer effective immediately. The appointment of Mr. Kawar is key in positioning HBP to successfully transition the Company with efficiency and effectiveness. Mr. Kawar has been working as the Financial Controller of HBP since July 2021. He also serves as a Financial Controller of Grove Corporate Services Ltd. ("Grove") which provides governance, accounting and administrative services to small-cap public and private companies in Canada. Mr. Kawar has 25 years' experience as CFO and/or Controller to several public companies in Canada. Previously, he was a project manager for an industrial minerals' operation in Saudi Arabia. Board Change • May 02
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 4 experienced directors. No highly experienced directors. Member of Scientific & Strategic Advisory Board Robert Gillies is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Apr 22
Helix BioPharma Corp. announced that it has received CAD 2.002 million in funding On April 21, 2022, Helix BioPharma Corp. closed the transaction. The company has issued 7,700,000 common shares at a price of CAD 0.26 per common share for gross proceeds of CAD 2,002,000. Mr. Jerzy Wilczewski, an insider of the company subscribed for 7,700,000 common shares as a part of the transaction. As a result of the closing of the transaction, Mr. Wilczewski owns or exercises control or direction over 31,167,153 common shares, representing approximately 19.85% of the issued and outstanding common shares of the company on a non-diluted basis, or approximately 27.15% on a partially diluted basis, assuming the full exercise of the 15,739,500 common share purchase warrants that Mr. Wilczewski owns or exercises control or direction over. Announcement • Apr 14
Helix BioPharma Corp. announced that it expects to receive CAD 2.002 million in funding Helix BioPharma Corp. announced a private placement of 7,700,000 common shares at price of CAD 0.26 per share for total gross proceeds of CAD 2,002,000 on April 13, 2022. The transaction will include participation from returning investor Jerzy Wilczewski, an insider of the company. The transaction is expected to close by the end of April 2022 and may close additional tranches for common shares prior to or following such date. Announcement • Apr 08
Helix Biopharma Corp. Announces Resignation of Krzysztof Saczek from the Board of Directors Helix BioPharma Corp. announced the resignation of Dr. Krzysztof Saczek from the Board of Directors with immediate effect. Announcement • Jan 30
Helix BioPharma Corp. Appoints Adam Uszpolewicz to its Board of Directors Helix BioPharma Corp. announced the voting results of the Company's annual and special meeting of shareholders held on January 28, 2022. In aaccordance with section11.3 of National Instrument 51-102 Continuous Disclosure Obligations, and the appointment of Mr. Adam Uszpolewicz to company's Board of Directors. Mr. Uszpolewicz brings 30 years of professional experience working in varied financial services sectors, including life, health and general insurance, asset management, pensions, banking and management consulting, and has significant experience leading M&A transactions. Board Change • Nov 02
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 5 experienced directors. No highly experienced directors. Interim CEO & Chairman of the Board Slawomir Majewski is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Oct 02
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 5 experienced directors. No highly experienced directors. Interim CEO & Chairman of the Board Slawomir Majewski is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • May 12
Helix BioPharma Corp. announced that it expects to receive CAD 10 million in funding from The Lind Partners, LLC Helix BioPharma Corp. (TSX:HBP) announced that it that it has entered into a definitive convertible security funding agreement with Lind Global Macro Fund, LP, a fund managed by The Lind Partners, LLC for gross proceeds of CAD 10,000,000 on May 11, 2021. The transaction will be done in two tranches, first for CAD 3,500,000 expected to occur on or around May 12, 2021 and second for CAD 6,500,000. Each convertible security issuable under the agreement will have a two-year term from the date of issuance and will accrue simple interest rate obligation of 8.75% per annum on the amount funded, which interest shall be prepaid and attributed to the face value of each convertible security upon the issuance, resulting in a face value of CAD 4,112,500 for the convertible security issuable under the first tranche. The investor will be entitled to convert the Convertible Securities subject to certain limitations, at a conversion price equal to 85% of the five-day trailing volume-weighted average price of the Common Shares prior to the date a notice of conversion is provided to the Company. The company has the option to buy-back 66.7% of the Convertible Securities in cash at any time with no penalty, subject to the option of Lind to convert up to 1/3 of the face value of the applicable Convertible Security into Common Shares at the time of such buy-back. The company has agreed to pay investor a 3% commitment fee of the amount funded under the first tranche and second tranche and due upon closing of each such tranche. In addition, in respect to the First Tranche, the Company has agreed to issue 1,957,056 common share purchase warrants exercisable into Shares for a period of 48 months at an exercise price of CAD 1.0283 per Common Share. Under the terms of the Agreement, the Company has also agreed to issue investor such number of Warrants as is equal to the quotient of one-half of the gross proceeds of Convertible Security issued under the Second Tranche divided by the 20-day VWAP of the Common Shares immediately prior to the closing date of the Second Tranche exercisable for a period of 48 months at a price per Common Share equal to the greater of the market price of the Common Shares immediately prior to the closing date of the Second Tranche and 115% of the 20- day VWAP of the Common Shares immediately prior to the closing date of the Second Tranche. The securities issuable under the Agreement will be subject to a hold period pursuant to Canadian securities laws, expiring four months and a day after the issuance of the applicable security. Closing of the transaction is subject to the approval of the Toronto Stock Exchange. Alpha Bronze LLC will be entitled to a finder’s fee equal to 5% of the proceeds. Announcement • Feb 18
Helix Biopharma Corp. Appoints Dr. Frank Gary Renshaw to the Scientific Advisory Board Helix BioPharma Corp. announced the appointment of Dr. Frank Gary Renshaw to the Company’s Scientific Advisory Board. Dr. Renshaw is currently the Chief Medical Officer of Zhejiang DTRM Biopharma Co. Ltd. Previous roles included Medical Oncology Director at Eisai; Global Executive Director Level II, Oncology and Hematology R&D at Celgene Corporate; Executive Director at Celsion Corporation and Global Clinical Lead; and Clinical Pharm Lead at Bayer Health Care Corporation. Dr. Renshaw participates in a number of oncology industry committees and task forces. Is New 90 Day High Low • Jan 26
New 90-day high: CA$1.01 The company is up 237% from its price of CA$0.30 on 27 October 2020. The Canadian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 21% over the same period. Announcement • Dec 31
Helix BioPharma Corp. announced that it has received CAD 3 million in funding Helix BioPharma Corp. (TSX:HBP) announced that it has closed a private placement of 6,000,000 units issued at a price of CAD 0.50 per unit for gross proceeds of CAD 3,000,000 on December 30, 2020. Each unit comprises of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.70 and have an expiry of five years from the date of issuance. Is New 90 Day High Low • Dec 31
New 90-day high: CA$0.42 The company is up 8.0% from its price of CA$0.39 on 30 September 2020. The Canadian market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Announcement • Dec 24
CAIAC Fund Management AG completed the acquisition of 51% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. (TSX:HBP). CAIAC Fund Management AG entered into a non-binding term sheet to acquire 51% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. (TSX:HBP) for PLN 6.7 million on June 26, 2020. Under the term sheet, Helix Immuno has accepted a non-binding offer from CAIAC Fund Management AG, in its capacity as designated trustee of an Alternative Investment Fund, that is currently in the process of being established and authorized by the Financial Market Authority in Liechtenstein. Helix BioPharma has also approved an increase in share capital of Helix Immuno Oncology and the issuance of up to 2.2 million Series B ordinary shares in the capital of Helix Immuno Oncology to enable it to issue up to 2.2 million series B ordinary shares by way of a private placement financing for aggregate gross proceeds of approximately PLN 3 million. Assuming the successful completion of the private placement of Helix Immuno Oncology, Helix BioPharma's shareholding in Helix Immuno Oncology is expected to decrease to approximately 42.5 % of the outstanding shares of Helix Immuno Oncology. In addition, Helix BioPharma has entered into agreements with Helix Immuno Oncology, pursuant to which it has cancelled an aggregate amount of certain amount of intercompany debt owed to Helix BioPharma by Helix Immuno Oncology. On November 9, 2020, CAIAC Fund Management AG entered definitive agreement to acquire 51% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp.
The transaction is subject to a number of conditions, including the approval of CAIAC Fund Management by Financial Market Authority in Liechtenstein, the raising of a minimum PLN 7.3 million by Financial Market Authority in Liechtenstein as well as regulatory approval of the transaction, if required and is scheduled to close on August 31, 2020. The Approval of the fund by FMA has been recently granted. As on August 31, 2020, the transaction is expected to close on September 30, 2020. The transaction is expected to close on October 30, 2020, as of September 30, 2020. As of November 9, 2020, completion is expected to take place during month of November 2020. ACM Alpha Consulting Management Est. will be entitled to a 12.5% fee in connection with the closing of the transaction.
CAIAC Fund Management AG completed the acquisition of 51% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. (TSX:HBP) on December 22, 2020. Announcement • Dec 06
Helix BioPharma Corp. announced that it has received CAD 1.1 million in funding Helix BioPharma Corp. (TSX:HBP) announced that it has closed a private placement of 2,200,000 units issued at a price of CAD 0.50 per unit for gross proceeds of CAD 1,100,000 on December 4, 2020. Each unit comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.70 and have an expiry of five years from the date of issuance. Is New 90 Day High Low • Dec 02
New 90-day low: CA$0.29 The company is down 42% from its price of CA$0.50 on 02 September 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 30% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Announcement • Nov 18
Helix BioPharma Corp., Annual General Meeting, Jan 28, 2021 Helix BioPharma Corp., Annual General Meeting, Jan 28, 2021. Is New 90 Day High Low • Oct 28
New 90-day low: CA$0.30 The company is down 44% from its price of CA$0.54 on 29 July 2020. The Canadian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Announcement • Oct 01
CAIAC Fund Management AG entered into a non-binding term sheet to acquire 51% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. (TSX:HBP) for PLN 6.7 million. CAIAC Fund Management AG entered into a non-binding term sheet to acquire 51% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. (TSX:HBP) for PLN 6.7 million on June 26, 2020. Under the term sheet, Helix Immuno has accepted a non-binding offer from CAIAC Fund Management AG, in its capacity as designated trustee of an Alternative Investment Fund, that is currently in the process of being established and authorized by the Financial Market Authority in Liechtenstein. Helix BioPharma has also approved an increase in share capital of Helix Immuno Oncology and the issuance of up to 2.2 million Series B ordinary shares in the capital of Helix Immuno Oncology to enable it to issue up to 2.2 million series B ordinary shares by way of a private placement financing for aggregate gross proceeds of approximately PLN 3 million. Assuming the successful completion of the private placement of Helix Immuno Oncology, Helix BioPharma's shareholding in Helix Immuno Oncology is expected to decrease to approximately 42.5 % of the outstanding shares of Helix Immuno Oncology. In addition, Helix BioPharma has entered into agreements with Helix Immuno Oncology, pursuant to which it has cancelled an aggregate amount of certain amount of intercompany debt owed to Helix BioPharma by Helix Immuno Oncology.
The transaction is subject to a number of conditions, including the approval of CAIAC Fund Management by Financial Market Authority in Liechtenstein, the raising of a minimum PLN 7.3 million by Financial Market Authority in Liechtenstein as well as regulatory approval of the transaction, if required and is scheduled to close on August 31, 2020. The Approval of the fund by FMA has been recently granted. As on August 31, 2020, the transaction is expected to close on September 30, 2020. The transaction is expected to close on October 30, 2020, as of September 30, 2020. Is New 90 Day High Low • Sep 22
New 90-day low: CA$0.41 The company is down 49% from its price of CA$0.80 on 24 June 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Announcement • Sep 01
Biotech Opportunity Fund managed by CAIAC Fund Management AG acquired 19.8% stake in Helix BioPharma Corp. (TSX:HBP) for CAD 13.2 million. Biotech Opportunity Fund managed by CAIAC Fund Management AG acquired 19.8% stake in Helix BioPharma Corp. (TSX:HBP) for CAD 13.2 million on August 27, 2020. Under the terms of the transaction, Biotech Opportunity Fund acquired 26.36 million for CAD 0.5 per share.
Biotech Opportunity Fund managed by CAIAC Fund Management AG completed the acquisition of 19.8% stake in Helix BioPharma Corp. (TSX:HBP) on August 27, 2020. Announcement • Aug 01
A third-party purchaser acquired 15.5% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. A third-party purchaser acquired 15.5% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. (TSX:HBP) on March 12, 2020. Under the terms of the transaction, Helix BioPharma Corp. disposed 1.7 million shares in Helix Immuno Oncology S.A. Helix BioPharma Corp. has closed a private placement financing of 5 million units of Helix BioPharma Corp. at a price of CAD 1.0332 per Unit, and the concurrent disposition of 1.7 million shares of Helix Immuno Oncology for aggregate gross proceeds of CAD 6 million. Following the disposition, Helix BioPharma Corp. now owns 51% of the outstanding shares of Helix Immuno Oncology S.A.
A third-party purchaser completed the acquisition of 15.5% stake in Helix Immuno Oncology S.A. from Helix BioPharma Corp. (TSX:HBP) on March 12, 2020. Announcement • Jul 17
Helix BioPharma Corp. to Report Q3, 2020 Results on Jul 30, 2020 Helix BioPharma Corp. announced that they will report Q3, 2020 results at 10:36 PM, GMT Standard Time on Jul 30, 2020 
